Literature DB >> 1472095

The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.

R J Knox1, F Friedlos, R F Sherwood, R G Melton, G M Anlezark.   

Abstract

A nitroreductase enzyme that has been isolated from Escherichia coli B is capable of bioactivating CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] to a cytotoxic agent, a property shared with the mammalian enzyme Walker DT diaphorase [NAD(P)H dehydrogenase (quinone), EC 1.6.99.2] as isolated from Walker cells. In contrast to Walker DT diaphorase, which can only reduce the 4-nitro group of CB1954, the E. coli nitroreductase can reduce either (but not both) nitro groups of CB1954 to the corresponding hydroxylamino species. The two hydroxylamino species are formed in equal proportions and at the same rates. CB1954 is reduced much more rapidly by the E. coli nitroreductase than by Walker DT diaphorase. If the reduction of CB1954 was carried out in the presence of V79 cells (which are insensitive to CB1954) a large cytotoxic effect was evident. This cytotoxicity was only observed under conditions in which the E. coli nitroreductase or Walker DT diaphorase reduced the drug. It is proposed that E. coli B nitroreductase would be a suitable enzyme for antibody-directed enzyme prodrug therapy (ADEPT) in combination with CB1954.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1472095     DOI: 10.1016/0006-2952(92)90672-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Crystallization and preliminary X-ray characterization of the Bacillus amyloliquefaciens YwrO enzyme.

Authors:  Majed M AbuKhader; John Heap; Cristina I De Matteis; Stephen W Doughty; Nigel Minton; Max Paoli
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-08-10

2.  Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.

Authors:  Chris Bot; Belinda S Hall; Noosheen Bashir; Martin C Taylor; Nuala A Helsby; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

3.  Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.

Authors:  Toru Shibata; Amato J Giaccia; J Martin Brown
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

4.  Nitroreductase-triggered activation of a novel caged fluorescent probe obtained from methylene blue.

Authors:  Jungeun Bae; Louis E McNamara; Manal A Nael; Fakhri Mahdi; Robert J Doerksen; Gene L Bidwell; Nathan I Hammer; Seongbong Jo
Journal:  Chem Commun (Camb)       Date:  2015-08-18       Impact factor: 6.222

5.  Prodrugs in Cancer Chemotherapy.

Authors:  Richard J Knox; Tom A Connors
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 6.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

7.  E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.

Authors:  S O Vass; D Jarrom; W R Wilson; E I Hyde; P F Searle
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

8.  2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

Authors:  N A Helsby; D M Ferry; A V Patterson; S M Pullen; W R Wilson
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

9.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

10.  Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.

Authors:  John T Heap; Jan Theys; Muhammad Ehsaan; Aleksandra M Kubiak; Ludwig Dubois; Kim Paesmans; Lieve Van Mellaert; Richard Knox; Sarah A Kuehne; Phillipe Lambin; Nigel P Minton
Journal:  Oncotarget       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.